Quince Therapeutics

• Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
• U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia